Answer
Infections, including pneumonia, occurred more often in elotuzumab-treated trial participants. Report fever, worsening cough or breathlessness promptly.
Sources for this answer
- Empliciti 300 mg and 400 mg powder for concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.